Filing identity and reporting period
Important identity mismatch: The supplied filing is for Ecology Coatings, Inc. and its subsidiary, not ABVC Biopharma, Inc. It is a Form 10-Q for the three months ended December 31, 2011 (the company’s fiscal first quarter of 2012), filed February 20, 2012. The financial statements are unaudited. Ecology develops UV-curable coatings for manufacturing markets.
Financial results and condition
| Metric | Quarter ended Dec. 31, 2011 | Comparable 2010 period |
|---|---|---|
| Revenue | $2,049 | $2,470 |
| General and administrative expenses | $461,026 | $370,647 |
| Operating loss | ($458,977) | ($368,177) |
| Net loss | ($277,139) | ($423,939) |
| Net loss available to common shareholders | ($468,911) | ($454,911) |
| Basic and diluted loss per share | ($0.03) | ($0.07) |
| Cash used in operating activities | ($293,558) | ($153,363) |
Revenue was negligible and fell about 17%. Operating loss widened about 25%, reflecting higher officer compensation and professional fees. Net loss improved mainly because the company recorded $228,802 of income from forgiveness of payables and debt; excluding that item, operating performance remained weak. The $170,000 beneficial-conversion preferred-stock charge and $21,772 of preferred stock dividends increased the loss attributable to common shareholders. Gross margin is not separately presented.
Cash fell from $71,784 at September 30, 2011 to $30,197 at December 31, 2011. Investing used $18,030, while $270,000 of preferred-stock financing partly offset cash use. Current assets were $52,712 against current liabilities of $1,677,908, implying a working-capital deficit of approximately $1.63 million. Total assets were $329,087; stockholders’ deficit was $1,348,821. Current liabilities included $250,000 of notes payable, $843,500 of related-party notes, and $447,024 of interest payable. The company reported a cumulative accumulated deficit of $29,243,330 in MD&A.
Material changes and significant items
- Officer salaries and benefits rose to $158,357 from $129,406; management attributed the increase to salary changes and additional employees. Professional fees rose to $93,642 from $30,168, partly because of audit fees associated with the 2011 Form 10-K.
- The company raised $270,000 by selling Series C convertible preferred shares in the quarter. Common shares outstanding increased from 14,158,506 at September 30 to 16,331,882 at December 31. The preferred shares are convertible at $0.06 per common share, creating substantial potential dilution.
- A $604,330 judgment was entered against the company on December 30, 2011 in Mitchell Shaheen’s suit over notes bearing 25% interest. The filing says the company had not appealed and was discussing satisfaction of the judgment.
- Related-party noteholder John Salpietra’s $600,000 secured note, secured by intellectual property, was extended to December 4, 2012. Certain related-party notes were in default. The filing also describes settlement of debt through share issuance and recognition of forgiveness income.
- Subsequent to quarter-end, the company entered a sale-and-leaseback transaction for laboratory and computer equipment with an entity owned by its board chairman; it also issued additional Series C preferred shares for $80,000 in January 2012.
Outlook, risks and controls
Management said additional funding was needed in spring 2012 to continue operations. It reported $385,000 remaining under the Fairmount Five investment agreement and estimated that, at the then-current cash-use rate, these funds would last only until April 2012. Failure to raise additional capital by then could require the company to curtail operations or seek bankruptcy protection. The filing states that substantial doubt exists about the company’s ability to continue as a going concern; no assurance of profitability or sufficient financing is provided.
Key risks include minimal revenue, continuing losses and negative cash flow; dependence on external financing; product-development and market-acceptance uncertainty; competition from larger coating companies; limited manufacturing and marketing capacity; reliance on suppliers and key personnel; intellectual-property risks; and dilution from preferred securities, options and warrants. Management reported disclosure controls were not effective, citing lack of segregation of duties in a small financial staff. No specific financial guidance was provided.
Important facts for investors to verify
- Confirm the filing’s registrant and period: the source is Ecology Coatings, not ABVC Biopharma.
- Reconcile inconsistent reported loss figures: the statements show a quarterly net loss of $277,139, while the going-concern note cites $232,435 for the same 2011 quarter. The filing also appears to confuse accumulated deficit with stockholders’ deficit in that note.
- Verify the status and accounting treatment of the $604,330 Shaheen judgment, given the balance sheet’s separate notes-payable presentation and other debt disclosures.
- Assess whether financing beyond the stated $385,000 remaining commitment was obtained and whether liquidity was sufficient to continue operations.
- Review the conversion terms and fully diluted share impact of preferred stock, options, warrants and other convertible securities.